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esophageal echocardiographic (TEE) study
entitled “Atherosclerosis of the aorta is
common in patients with severe aortic
stenosis: An intraoperative transesopha-
geal echocardiographic study.”1 This in-
triguing study found a strong association
between the presence of severe aortic ste-
nosis (AS) and the presence and severity
of aortic atheromas, suggesting that AS
might be a manifestation of the athero-
sclerotic process. However, we feel that a
few additional comments are necessary.
Evident from previous TEE work, we
demonstrated that the average grade of
aortic atherosclerosis (AA) using a five-
grade scale is significantly increased in
AS patients with normal epicardial coro-
nary arteries (1.440.64) as compared to
control subjects without valvular or cor-
onary heart disease (0.620.74). The de-
gree of AA in AS patients is also similar
to patients with significant left anterior
descending coronary artery (LAD) dis-
ease (1.27 0.72).2 Furthermore, another
TEE study verified that, neither age, gen-
der, high blood pressure, diabetes melli-
tus, hypercholesterolaemia nor coronary
flow velocity reserve were suitable for
the prediction of AS patients with signif-
icant LAD stenosis from AS subjects
with normal epicardial coronary arteries.
Only the grade of AA is suitable for the
prediction of AS patients with significant
LAD stenosis from AS subjects with nor-
mal epicardial coronary arteries. With re-
spect to demographic, clinical and echo-
cardiographic data, only the prevalence
of grade 2 or 3 AA (aortic plaque) is
significantly increased in AS patients
with significant stenosis of the LAD.3
Aortic distensibility can also be eval-
uated during TEE using aortic and blood
pressure data. Different elastic properties
of the descending aorta can be assessed
by TEE as elastic modulus and Young’s
circumferential static elastic modulus.
Decreased aortic distensibility (increased
elastic moduli) and thus, increased stiff-
ness of the descending aorta were dem-
onstrated in AS patients with normal epi-
cardial coronary arteries. This result
supports that decreased aortic distensibil-
ity in AS patients is an early manifesta-
tion of the atherosclerotic process and/or
decreased perfusion of the aorta.2,5 Our
initial results suggest that there are no
differences in these values characterizing
aortic distensibility if mitral stenosis is
associated with AS.4
Overall, these results confirm that
TEE is a valuable method for the mor-
phological (grade of aortic atherosclero-
sis) and functional (elastic properties of
the aorta) evaluation of the descending
aorta in AS patients. There is a strong
relationship between the aortic athero-
sclerosis/distensibility and AS, suggest-
ing that aortic valve calcification might
represent an atherosclerosis-like process.
However further investigations are war-
ranted.
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Association between
cyclooxygenase and epidermal
growth factor receptor pathways in
non–small cell lung cancer
To the Editor:
We read with great interest the article by
Sievers and associates.1 In their orthotopic
murine model of lung cancer with adenocar-
cinoma, they showed inhibition of tumor
growth with a low-dose cyclooxygenase-2
(COX-2) inhibitor, celecoxib. In their arti-
cle, they discussed different mechanisms of
association between COX-2 inhibition and
attenuation of tumor growth in non–small
cell lung cancer (NSCLC), and we want to
propose another. COX (or prostaglandin
endoperoxide synthase) catalyzes the con-
version of arachidonic acid to prostaglan-
din (PG) H2. This unstable endoperoxide is
then converted into PGE2, PGI2, PGD2,
PGF2, or thromboxane A2 by each respec-
tive PG synthase. Most tumors that express
COX have been found to contain high lev-
els of PGE2 and the microsomal PGE syn-
thase enzyme. Presumably, these bioactive
lipid products of COX, such as PGE2, are
responsible for some of the proneoplastic
effects mediated by this enzyme.2 The epi-
dermal growth factor receptor (EGFR) is a
member of the ErbB family of transmem-
brane tyrosine kinase receptors. The ex-
pression of EGFR is common in a number
of normal epithelial tissues, and the expres-
sion of EGFR is elevated in several solid
tumors. In NSCLC, overexpression of
EGFR has been reported to be present in
more than 50% of cases in several series.
Receptor activation leads to recruitment and
phosphorylation of several downstream intra-
cellular substrates, leading to mitogenic sig-
naling and other tumor-promoting cellular
activities. In addition to this, several retro-
spective studies have identified the expres-
sion of EGFR as a negative prognostic fac-
tor in patients with resected early NSCLC.3
Sheng and colleagues4 found that PGE2 ini-
tially binds t o its cognate receptor, EP4, in
LS-174T cells, which in turn activates sig-
nals that led to dramatic changes in cell
biology. One study demonstrated that the
PGE2-induced migration and invasion oc-
cur by rapid transactivation and phosphor-
ylation of EGFR in developing carcinoma
cells.5 Within minutes after treatment,
PGE2 induces the activation of Akt. This
effect is completely abolished by EGFR-
specific tyrosine kinase inhibitors, provid-
ing evidence for the role of the EGFR in
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this response. The rapid transactivation of
EGFR occurs by an intracellular Src-
mediated event, but not through the release
of an extracellular epidermal growth factor–
like ligand. These results suggest that the
early effects of COX-2– derived PGE2 are
in part mediated by EGFR, and this trans-
activation is responsible for subsequent
downstream effects, including the stimula-
tion of cell migration and invasion.5 In the
light of this information, we propose that
celecoxib may inhibit downstream signal-
ing of EGFR by decreasing the COX-2
protein and PGE2 levels, resulting in tumor
growth inhibition in NSCLC.
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Reply to the Editor:
We thank Ates and colleagues for their
thoughtful comments. We agree that there
is an interrelationship between the cyclo-
oxygenase-2 (COX-2) enzyme (and prosta-
noid products) and the epidermal growth
factor receptor (EGFR) family. In an im-
portant article, Pai and colleagues1 re-
ported that COX-2/prostaglandin E2 trans-
activates the EGFR receptor, with resultant
activation of downstream signaling.1 Sim-
ilarly it has been proposed that EGFR sig-
naling can increase COX-2 activity. These
findings have given cause for initiation of
human trials of combination therapy with
both EGFR receptor inhibitors and cele-
coxib in patients with non–small cell can-
cer, with some exciting initial results. How-
ever, the interaction between the two is
complex and as yet incompletely understood. 
Recently, Richardson and colleagues2 found
that COX-2 protein levels are independent of
EGFR expression or activation in patients
with non–small cell cancer.2 We have found
that combination therapy (EGFR receptor
blocker together with COX-2 blockade by
celecoxib) are occasionally antagonistic (at
least in one cell line) in an animal ortho-
topic lung cancer model. When under-
standing the interaction, though, it is im-
portant to realize that levels of the COX-2
enzyme (both messenger RNA and protein)
are variably affected by celecoxib, but the
activity of the enzyme is profoundly
blocked even by low doses of the drug.
With regard to final sentence of the letter,
we would agree that celecoxib decreases
PGE2 levels (but not COX-2 levels) and
that interactions with the EGFR cascade
probably account for some of the antineo-
plastic activity of the compound.
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